Vertex Pharmaceuticals (VRTX) R&D In Process: 2021-2025
Historic R&D In Process for Vertex Pharmaceuticals (VRTX) over the last 5 years, with Sep 2025 value amounting to $54.5 million.
- Vertex Pharmaceuticals' R&D In Process rose 263.33% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.0 million, marking a year-over-year decrease of 96.40%. This contributed to the annual value of $4.6 billion for FY2024, which is 778.09% up from last year.
- Per Vertex Pharmaceuticals' latest filing, its R&D In Process stood at $54.5 million for Q3 2025, which was up 2,377.27% from $2.2 million recorded in Q2 2025.
- In the past 5 years, Vertex Pharmaceuticals' R&D In Process ranged from a high of $4.4 billion in Q2 2024 and a low of $1.7 million during Q2 2021.
- Moreover, its 3-year median value for R&D In Process was $54.5 million (2025), whereas its average is $475.6 million.
- In the last 5 years, Vertex Pharmaceuticals' R&D In Process soared by 17,255.00% in 2023 and then tumbled by 99.95% in 2025.
- Quarterly analysis of 5 years shows Vertex Pharmaceuticals' R&D In Process stood at $126.5 million in 2021, then slumped by 82.13% to $22.6 million in 2022, then decreased by 21.24% to $17.8 million in 2023, then surged by 391.57% to $87.5 million in 2024, then surged by 263.33% to $54.5 million in 2025.
- Its R&D In Process was $54.5 million in Q3 2025, compared to $2.2 million in Q2 2025 and $19.8 million in Q1 2025.